Literature DB >> 29705831

Deprescribing Benzodiazepines in Older Patients: Impact of Interventions Targeting Physicians, Pharmacists, and Patients.

Brendan J Ng1,2,3, David G Le Couteur1,3, Sarah N Hilmer4,5.   

Abstract

Benzodiazepines (BZDs; including the related Z-drugs) are frequently targets for deprescribing; long-term use in older people is harmful and often not beneficial. BZDs can result in significant harms, including falls, fractures, cognitive impairment, car crashes and a significant financial and legal burden to society. Deprescribing BZDs is problematic due to a complex interaction of drug, patient, physician and systematic barriers, including concern about a potentially distressing but rarely fatal withdrawal syndrome. Multiple studies have trialled interventions to deprescribe BZDs in older people and are discussed in this narrative review. Reported success rates of deprescribing BZD interventions range between 27 and 80%, and this variability can be attributed to heterogeneity of methodological approaches and limited generalisability to cognitively impaired patients. Interventions targeting the patient and/or carer include raising awareness (direct-to-consumer education, minimal interventions, and 'one-off' geriatrician counselling) and resourcing the patient (gradual dose reduction [GDR] with or without cognitive behavioural therapy, teaching relaxation techniques, and sleep hygiene). These are effective if the patient is motivated to cease and is not significantly cognitively impaired. Interventions targeted to physicians include prescribing interventions by audit, algorithm or medication review, and providing supervised GDR in combination with medication substitution. Pharmacists have less frequently been the targets for studies, but have key roles in several multifaceted interventions. Interventions are evaluated according to the Behaviour Change Wheel. Research supports trialling a stepwise approach in the cognitively intact older person, but having a low threshold to use less-consultative methods in patients with dementia. Several resources are available to support deprescribing of BZDs in clinical practice, including online protocols.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29705831     DOI: 10.1007/s40266-018-0544-4

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  143 in total

1.  Association between use of benzodiazepines and risk of fractures: a meta-analysis.

Authors:  D Xing; X L Ma; J X Ma; J Wang; Y Yang; Y Chen
Journal:  Osteoporos Int       Date:  2013-09-07       Impact factor: 4.507

Review 2.  Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal.

Authors:  B Dell'osso; M Lader
Journal:  Eur Psychiatry       Date:  2012-04-20       Impact factor: 5.361

3.  Economic impact of inappropriate benzodiazepine prescribing and related drug interactions among elderly persons.

Authors:  Pierre-Alexandre Dionne; Helen-Maria Vasiliadis; Eric Latimer; Djamal Berbiche; Michel Preville
Journal:  Psychiatr Serv       Date:  2013-04-01       Impact factor: 3.084

4.  Variation in benzodiazepine and antipsychotic use in people aged 65 years and over in New Zealand.

Authors:  Gary Jackson; Catherine Gerard; Nikolai Minko; Nirasha Parsotam
Journal:  N Z Med J       Date:  2014-06-20

5.  Potentially inappropriate psychotropic prescription at discharge is associated with lower functioning in the elderly psychiatric inpatients. A cross-sectional study.

Authors:  Guillaume Fond; Claire Fajula; Daniel Dassa; Lore Brunel; Christophe Lançon; Laurent Boyer
Journal:  Psychopharmacology (Berl)       Date:  2016-04-30       Impact factor: 4.530

6.  The costs of benzodiazepine-associated hospital-treated fall Injuries in the EU: a Pharmo study.

Authors:  Martien J M Panneman; Wim G Goettsch; Piotr Kramarz; Ron M C Herings
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Benzodiazepine dependence and withdrawal in elderly patients.

Authors:  E Schweizer; W G Case; K Rickels
Journal:  Am J Psychiatry       Date:  1989-04       Impact factor: 18.112

8.  Analysis of benzodiazepine withdrawal program managed by primary care nurses in Spain.

Authors:  Cristina Lopez-Peig; Xavier Mundet; Bartomeu Casabella; Jose Luis del Val; David Lacasta; Eduard Diogene
Journal:  BMC Res Notes       Date:  2012-12-13

Review 9.  Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users.

Authors:  Lone Baandrup; Bjørn H Ebdrup; Jesper Ø Rasmussen; Jane Lindschou; Christian Gluud; Birte Y Glenthøj
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15

10.  Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study.

Authors:  Shelly L Gray; Sascha Dublin; Onchee Yu; Rod Walker; Melissa Anderson; Rebecca A Hubbard; Paul K Crane; Eric B Larson
Journal:  BMJ       Date:  2016-02-02
View more
  26 in total

Review 1.  Guidance for appropriate use of psychotropic drugs in older people.

Authors:  Andreas Capiau; Katrien Foubert; Annemie Somers; Mirko Petrovic
Journal:  Eur Geriatr Med       Date:  2021-01-08       Impact factor: 1.710

Review 2.  Barriers and enablers for deprescribing benzodiazepine receptor agonists in older adults: a systematic review of qualitative and quantitative studies using the theoretical domains framework.

Authors:  Perrine Evrard; Catherine Pétein; Jean-Baptiste Beuscart; Anne Spinewine
Journal:  Implement Sci       Date:  2022-07-08       Impact factor: 7.960

3.  Applying the intervention Complexity Assessment Tool to brief interventions targeting long-term benzodiazepine receptor agonist use in primary care: Lessons learned.

Authors:  Aisling Barry; Simon Lewin; Cathal A Cadogan
Journal:  BMC Prim Care       Date:  2022-07-16

Review 4.  Deprescribing of non-antiretroviral therapy in HIV-infected patients.

Authors:  José-Ramón Blanco; Ramón Morillo; Vicente Abril; Ismael Escobar; Enrique Bernal; Carlos Folguera; Fátima Brañas; Mercedes Gimeno; Olatz Ibarra; José-Antonio Iribarren; Alicia Lázaro; Ana Mariño; María-Teresa Martín; Esteban Martinez; Luis Ortega; Julian Olalla; Aguas Robustillo; Matilde Sanchez-Conde; Miguel-Angel Rodriguez; Javier de la Torre; Javier Sanchez-Rubio; Montse Tuset
Journal:  Eur J Clin Pharmacol       Date:  2019-12-21       Impact factor: 2.953

5.  Point Prevalence Survey of Benzodiazepine and Sedative-Hypnotic Drug Use in Hospitalized Adult Patients.

Authors:  Heather L Neville; Mia Losier; Jennifer Pitman; Melissa Gehrig; Jennifer E Isenor; Laura V Minard; Ellen Penny; Susan K Bowles
Journal:  Can J Hosp Pharm       Date:  2020-06-01

6.  Trends in benzodiazepine receptor agonists use and associated factors in the Belgian general older population: analysis of the Belgian health interview survey data.

Authors:  Catherine Pétein; Anne Spinewine; Séverine Henrard
Journal:  Ther Adv Psychopharmacol       Date:  2021-05-25

Review 7.  Interventions to optimize medication use in nursing homes: a narrative review.

Authors:  Anne Spinewine; Perrine Evrard; Carmel Hughes
Journal:  Eur Geriatr Med       Date:  2021-03-09       Impact factor: 1.710

8.  Patient and Physician Perspectives of Deprescribing Potentially Inappropriate Medications in Older Adults with a History of Falls: a Qualitative Study.

Authors:  Erin E Hahn; Corrine E Munoz-Plaza; Eric Anthony Lee; Tiffany Q Luong; Brian S Mittman; Michael H Kanter; Hardeep Singh; Kim N Danforth
Journal:  J Gen Intern Med       Date:  2021-01-19       Impact factor: 6.473

9.  The impact of in hospital patient-education intervention on older people's attitudes and intention to have their benzodiazepines deprescribed: a feasibility study.

Authors:  Danijela Gnjidic; Hui Min Magdalene Ong; Celeste Leung; Jesse Jansen; Emily Reeve
Journal:  Ther Adv Drug Saf       Date:  2019-01-17

10.  Deprescribing of Medicines in Care Homes-A Five-Year Evaluation of Primary Care Pharmacist Practices.

Authors:  Ana Alves; Shaun Green; Delyth H James
Journal:  Pharmacy (Basel)       Date:  2019-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.